Clinical trials: Acute Hepatitis C
HIV
Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)
The purpose of the study is to explore the treatment of patients with acute hepatitis C infection (infection acquired within the last 6 months) who are also infected with human immunodeficiency virus (HIV).
- Trial name
- CHAT (NCT02006745)
- Testing
- Ribavirin, Telaprevir
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- St Stephens Aids Trust
Hepatitis C, Acute
Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P
An open label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin or glecaprevir/pibrentasvir for people with recently acquired hepatitis C virus infection with or…
- Trial name
- TARGET3D (NCT02634008)
- Testing
- Paritaprevir/ritonavir/ombitasvir, Dasabuvir, Ribavirin
- Where
- 11 sites in Australia, New Zealand and 1 more
- Volunteers
- 83 people
- Sponsor
- Kirby Institute
Hepatitis C
DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)
The purpose of the study is to examine whether patients who have acute or early chronic hepatitis C virus (HCV) infection can be treated effectively and safely with an interferon-sparing regimen that combines a new direct acting…
- Trial name
- DARE-C II (NCT02156570)
- Testing
- Sofosbuvir and ribavirin
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Kirby Institute
Acute Hepatitis C
Australian Trial in Acute Hepatitis C Recall Study
A single long-term follow up assessment of an established multi-centre, prospective longitudinal cohort study of patients for clinical, psychosocial, immunovirological outcomes 4 to 8 years after previous treatment for recently…
- Trial name
- ATAHC Recall (NCT02000063)
- Where
- 3 sites in Australia
- Volunteers
- 50 people
- Sponsor
- Kirby Institute
Hepatitis, Liver Diseases
Evaluation of Orthohepevirus C Infection as an Emerging Cause of Zoonotic Origin Disease
The main objective of this study is to evaluate the prevalence and the clinical impact of Orthohepevirus C infection in different human populations, and to determine its zoonotic origin comparing the sequences obtained in both…
- Conditions
- Hepatitis, Liver Diseases, Acute Hepatitis, Chronic Hepatitis
- Trial name
- NCT05062967
- Where
- 10 sites in Spain
- Volunteers
- 3,257 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Chronic Pain, Chronic Pain Syndrome
Outcomes Mandate National Integration With Cannabis as Medicine
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
- Conditions
- Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma
- Trial name
- OMNI-Can (NCT03944447)
- Testing
- Cannabis, Medical, RYAH-Medtech Inhaler
- Where
- 17 sites in United States
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- OMNI Medical Services, LLC
Acute Hepatitis C, Human Immunodeficiency Virus
Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV
New and recently EMA/FDA approved direct acting antiviral (DAA) combination therapies cure 95% or more of the patients chronically infected with HCV genotype 1 and 4.
- Conditions
- Acute Hepatitis C, Human Immunodeficiency Virus, Hepatitis C
- Trial name
- DAHHS-2 (NCT02600325)
- Testing
- Grazoprevir/Elbasvir 100mg/50mg
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 80 people
- Sponsor
- Erasmus Medical Center
Cirrhosis, End Stage Liver Disease
Mild Hypothermia and Acute Kidney Injury in Liver Transplantation
Acute kidney injury (AKI), or worsening kidney function, is a common complication after liver transplantation (20-90% in published studies).
- Conditions
- Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications
- Trial name
- MHALT (NCT03534141)
- Testing
- Esophageal cooling/warming device, Mild hypothermia, Normothermia
- Where
- 3 sites in United States
- Volunteers
- 175 people
- Sponsor
- University of California, San Francisco
Acute Hepatitis C, HIV
To Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection
This study plans to evaluate what happens to the brain in patients with HIV and early hepatitis C. The investigators will be comparing 3 groups of individuals: Group 1: Individuals with HIV infection and acute (early) hepatitis C…
- Conditions
- Acute Hepatitis C, HIV, HIV Infections
- Trial name
- NCT00959166
- Testing
- PET scan
- Where
- United Kingdom
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Acute Hepatitis C
HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection
This is an open-label, single arm, multicenter, pilot-study to compare the efficacy and safety of LDV/SOF fixed dose combination (FDC) in subjects with acute genotype 1 HCV infection.
- Trial name
- NCT02309918
- Testing
- LDV/SOF FDC
- Where
- 20 sites in Germany
- Volunteers
- 20 people
- Sponsor
- HepNet Study House, German Liverfoundation
Investigate the Renal Effect of DAAs on Egyption Patients After Completion of Treatment
Prevalence of Kidney Injury in Patients With HCV Treated With Sofuspovir Containing DAA Therapy
this study aims is to investigate the occurrence of AKI during antiviral therapy, defined as an increase of 0.3 mg/dL or 50% at least in serum creatinine level when compared with baseline values or more than a 25% reduction in…
- Trial name
- NCT04267458
- Testing
- evaluation of sofuspovir containing DAA regien expected insult on kidney
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Cairo University
Substance-Related Disorders, Hepatitis
Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug Users
Injection drug use accounts for transmission of a high proportion of Hepatitis C Virus (HCV) infections. The purpose of this trial is to investigate the effectiveness of pegylated interferon in treating injection drug users…
- Trial name
- NCT00194480
- Testing
- Pegylated Interferon
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Hepatitis C
Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213)
Acute hepatitis C is a liver disease related to a virus: hepatitis C virus (HCV). The type of Hepatitis C Virus present in Egypt (genotype 4), has the reputation to respond poorly to treatment at the chronic hepatitis stage.
- Trial name
- NCT00158522
- Testing
- pegylated interferon alpha2a
- Where
- Egypt
- Volunteers
- 31 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Acute Hepatitis C
Treatment of Recently Acquired Hepatitis C Virus Infection
To determine whether response guided treatment with pegylated interferon +/- ribavirin is effective for the treatment of recently acquired hepatitis C infection.
- Trial name
- ATAHC-II (NCT01336010)
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 8 sites in Australia
- Volunteers
- 82 people
- Sponsor
- Kirby Institute
Acute Hepatitis A, Acute Hepatitis B
Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis
The purpose of this study is to assess whether two higher doses (280mg or 420mg three times daily)of silymarin therapy are safe and tolerable, and shorten the illness in patients with acute viral hepatitis compared to placebo.
- Conditions
- Acute Hepatitis A, Acute Hepatitis B, Acute Hepatitis C, Acute Hepatitis E
- Trial name
- NCT00755950
- Testing
- Silymarin, Lactose monohydrate
- Where
- 3 sites in Egypt
- Volunteers
- 70 people
- Sponsor
- University of Maryland, Baltimore
HIV-1 Infection, Hepatitis
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
Early identification of acute HCV infection is essential to prevent chronic infections and the long-term liver disease complications that may occur.
- Trial name
- SWIFT-C (NCT02128217)
- Testing
- Sofosbuvir, Ribavirin, Ledipasvir/Sofosbuvir
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Hepatitis C
HCV Treatment Initiation During Acute Psychiatric Admission
Hepatitis C virus (HCV) disproportionally affects certain populations, including those facing substance use and mental health challenges.
- Trial name
- NCT04625322
- Testing
- HCV care provided by hospitalist during acute psychiatric admission
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- University Health Network, Toronto
Hepatitis C, Human Immunodeficiency Virus
Dutch Acute HCV in HIV Study (DAHHS)
Prospective open label proof of concept feasibility interventional clinical trial in which 60 acute HCV genotype 1 patients co-infected with HIV will receive 12 weeks of boceprevir in addition to Standard Of Care Peginterferon +…
- Trial name
- DAHHS (NCT01912495)
- Testing
- Boceprevir
- Where
- 9 sites in Netherlands
- Volunteers
- 65 people
- Sponsor
- Erasmus Medical Center
Ebola Virus Disease, Marburg Virus Disease
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
Primary Objective: To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10^11 particle units (PU) to healthy adults.
- Trial name
- NCT04723602
- Testing
- cAd3-Marburg, cAd3-EBO-S
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Hepatitis C
Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C
Interferon-based monotherapy has been considered effective to treat acute hepatitis C in ordinary patients. However, the efficacy of this treatment has not been evaluated in prospective interventional studies for dialysis…
- Trial name
- NCT00917358
- Testing
- Pegylated interferon alfa-2a
- Where
- 5 sites in Taiwan
- Volunteers
- 42 people
- Sponsor
- National Taiwan University Hospital